scholarly journals Plasma cytokines for predicting diabetic retinopathy among type 2 diabetic patients via machine learning algorithms

Aging ◽  
2020 ◽  
Author(s):  
Bin Cao ◽  
Ning Zhang ◽  
Yuanyuan Zhang ◽  
Ying Fu ◽  
Dong Zhao
Diabetes ◽  
2018 ◽  
Vol 67 (Supplement 1) ◽  
pp. 599-P ◽  
Author(s):  
SARA CHERCHI ◽  
ALFONSO GIGANTE ◽  
PIERPAOLO CONTINI ◽  
DANILA PISTIS ◽  
ROSANGELA M. PILOSU ◽  
...  

Diabetes ◽  
2019 ◽  
Vol 68 (Supplement 1) ◽  
pp. 782-P
Author(s):  
YATIR BEN SHLOMO ◽  
SHAHAR AZULAY ◽  
TALI RAVEH-SADKA ◽  
YOSSI COHEN ◽  
ARIEL HANEMANN

2015 ◽  
Vol 235 (2) ◽  
pp. 87-96
Author(s):  
Jen-Chieh Lin ◽  
Mei-Shu Lai

Objective: To evaluate the association between the development of sight-threatening diabetic retinopathy (STDR) and antihypertensive drugs (AHDs) use among type 2 diabetic patients with concomitant hypertension. Methods: Type 2 diabetic patients aged 20-100 years who had at least one prescription for AHDs between 2000 and 2011 were identified from the Longitudinal Health Insurance Database (LHID) 2005. The incidence rates of STDR were followed and Cox proportional hazard models were used to analyze the risk associated with AHDs. Results: Users of angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) were associated with a significantly higher risk than users of calcium channel blockers (CCBs), independent of baseline characteristics. After adjusting for time-varying use of concomitant medications for propensity score-matched or -unmatched cohorts, the results showed that patients receiving ACEIs/ARBs and CCBs were associated with a significantly greater risk compared with β-blocker users. Conclusions: Our study did not support a superiority of ACEIs/ARBs and CCBs over β-blockers for lowering the progression of diabetic retinopathy.


2014 ◽  
Vol 46 (7) ◽  
pp. 1375-1381 ◽  
Author(s):  
Huiyan Zhang ◽  
Jianyong Wang ◽  
Gui-shuang Ying ◽  
Liping Shen ◽  
Zhe Zhang

Sign in / Sign up

Export Citation Format

Share Document